Novo Nordisk's top investor seizes board control in weight-loss drug battle

The Novo Nordisk Foundation, the controlling shareholder of Novo Nordisk, is asserting greater control over the drugmaker's board, leading to the resignation of current chair Helge Lund and six independent board members. This decisive action, driven by dissatisfaction with the company's strategic pace and performance in the critical U.S. market, aims to install former CEO Lars Rebien Sorensen as the new chair to sharpen focus on reviving sales of its blockbuster weight-loss drug Wegovy amidst intense competition from Eli Lilly. The foundation criticized the outgoing board for being slow to adapt to U.S. market shifts, signaling a significant strategic pivot to regain market share and investor confidence after Novo's shares plunged over 40% this year.

Analysis

The Novo Nordisk Foundation, controlling shareholder of Novo Nordisk (NVO), has orchestrated a significant board overhaul, leading to the immediate resignation of Chairman Helge Lund and six independent board members. This stems from the Foundation's dissatisfaction with the outgoing board's slow adaptation to U.S. market shifts and cautious management. Former CEO Lars Rebien Sorensen is proposed as the new chair to sharpen focus on the U.S. market and revive Wegovy sales.

This leadership change follows a period of significant underperformance, with NVO shares plunging over 40% this year as rival Eli Lilly (LLY) gained market share. The Foundation criticized the previous board for failing to adequately address the growing direct-to-consumer and mass markets in the U.S., signaling a strategic pivot.

The proposed new board, led by Sorensen, supports new CEO Mike Doustdar's restructuring efforts, including 9,000 job cuts. While the Foundation emphasizes renewed U.S. focus, some investors express skepticism regarding the former CEO's return, and the company faces ongoing pressure from U.S. President Donald Trump on drug pricing.

Novo's shares closed down 1.5% post-announcement, reflecting an "uncertain" tone and "moderately negative" sentiment (-0.6 for NVO). This internal power struggle and strategic pivot aim to restore investor confidence and growth in a "rapidly changing environment" amidst intense competition.

Key Decisions for Investors

• Investors should closely monitor the execution of the new board's U.S. market strategy, particularly initiatives aimed at direct-to-consumer and mass markets, as this will be crucial for Wegovy's sales recovery against Eli Lilly.
• Evaluate the implications of this significant leadership change on corporate governance and long-term strategic stability, considering the expressed investor skepticism and the "uncertain" market tone.
• Assess the potential impact of ongoing U.S. drug pricing pressures, as highlighted by President Trump's stance, which could affect Novo Nordisk's profitability despite renewed market focus.